Eptifibatide has been assigned to pregnancy category B by the FDA. Animal data have failed to reveal evidence of fetotoxicity after administration of doses equivalent to 4 times the maximum recommended human daily dose. There are no adequate or controlled data from human pregnancy studies. Eptifibatide should only be used during pregnancy when need has been clearly established.

See references

There are no data on the excretion of eptifibatide in human milk. Because many drugs are excreted in human milk, caution should be exercised when eptifibatide is administered to a nursing mother.

See references